24/7 Wall St. takes a look at what is coming up in the FDA calendar regarding biotech and pharmaceutical companies expecting updates to their drug pipeline or other major events for the rest of 2018.
Despite Brexit absolutely rocking the market over a week ago, the broad markets made a solid comeback leading most people to believe that this was just one big head fake. Some companies made runs in...
Ampio Pharmaceuticals, Inc. (NYSEMKT: AMPE) is watching its shares get cut in half on Thursday after news of a failed late-stage trial. The company announced the results of its Ampion PIVOT clinical...
Ampio Pharmaceuticals made waves in the market on Tuesday morning and it looked like a day trader’s dream.
Source: ThinkstockApril 20, 2015: Here are four stocks among the 26 equities making new 52-week lows today.Iconix Brand Group Inc. (NASDAQ: ICON) dropped nearly 20% on Monday to post a new 52-week...
Ampio announced Monday that a Phase 3 for the treatment pain due to osteoarthritis of the knee did not reach its primary endpoint against a saline control.
Source: ThinkstockAugust 27, 2014: Among the 11 stocks making new 52-week lows today were the following three firms:Ampio Pharmaceuticals Inc. (NYSEMKT: AMPE) dropped another 4.5% on Wednesday to...
Source: ThinkstockAugust 26, 2014: Among the 23 stocks making new 52-week lows today were the following four firms:Ampio Pharmaceuticals Inc. (NYSEMKT: AMPE) dropped nearly 5%% on Tuesday to post a...
These are the top analyst upgrades and downgrades from 24/7 Wall St. for Friday, August 22, 2014.
Sometimes stocks trading under $10 have incredible upside price targets from analysts. Lower-priced stocks are often among the riskiest, but some investors feel like there is larger room for upside.
Markets opened slightly lower this morning as everyone seemed to be waiting for the announcement from Apple Inc. (NASDAQ: AAPL) regarding its $97 billion cash pile (our coverage here). Financial...
Drug maker Ampio Pharmaceuticals Inc. (NASDAQ: AMPE) reported this morning that clinical trials of the company’s Optina treatment for a type of macular disease have been successful:A preliminary...
Markets opened lower this morning on mixed reaction to the $641 billion borrowing spree from the European Central Bank. Technology stocks were weighed down by poor earnings report and uninspired...